Healios K.K. | Income Statement

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
500,000.00
279,997.00
98,167.00
77,640.00
27,666.00
78,000
Cost of Goods Sold (COGS) incl. D&A
-
149,231.00
172,861.00
178,455.00
103,635.00
78,000
Gross Income
-
130,766.00
74,694.00
100,815.00
75,969.00
78,000
SG&A Expense
293,267.00
704,175.00
985,722.00
3,406,649.00
2,272,238.00
4,985,000
EBIT
194,936.00
573,409.00
1,060,416.00
3,507,464.00
2,348,207.00
5,063,000
Unusual Expense
15.00
-
19,501.00
90.00
1,649.00
6,000
Non Operating Income/Expense
12,977.00
98,910.00
82,787.00
106,643.00
601,871.00
5,000
Interest Expense
2,058.00
1,144.00
-
26,010.00
26,862.00
28,000
Pretax Income
179,916.00
476,503.00
958,128.00
3,426,741.00
1,771,550.00
5,091,000
Income Tax
94,775.00
6,803.00
25.00
6,813.00
5,102.00
5,000
Consolidated Net Income
85,141.00
483,306.00
958,103.00
3,433,554.00
1,776,653.00
5,097,000
Net Income
85,141.00
480,712.00
958,103.00
3,433,554.00
1,776,653.00
5,097,000
Net Income After Extraordinaries
85,141.00
480,712.00
958,103.00
3,433,554.00
1,776,653.00
5,097,000
Net Income Available to Common
85,141.00
480,712.00
958,103.00
3,433,554.00
1,776,653.00
5,097,000
EPS (Basic)
2.67
14.44
25.60
84.33
39.73
103.52
Basic Shares Outstanding
31,846.50
33,295.50
37,423.40
40,715.10
44,716.10
49,238.10
EPS (Diluted)
2.67
14.44
25.60
84.33
39.73
103.52
Diluted Shares Outstanding
31,846.50
33,295.50
37,423.40
40,715.10
44,716.10
49,238.10
EBITDA
206,733.00
454,082.00
896,947.00
3,338,154.00
2,247,891.00
4,985,000
Minority Interest Expense
-
2,594.00
-
-
-
-
Equity in Affiliates (Pretax)
-
860.00
-
-
-
-

About Healios

View Profile
Address
World Trade Center Building, 15/F
Tokyo Tokyo 105
Japan
Employees -
Website http://www.healios.co.jp
Updated 07/08/2019
Healios KK engages in the development and sale of ophthalmological surgery adjuvants. It aims to commercialize pharmaceutical hiPSC derived retinal pigment epithelium (RPE) cell transplantation for the treatment of age-related macular degeneration. The firm develops therapies for the regeneration of retinal function and to improve visual function in those affected with retinal degenerative diseases.